Cogent (COGT) Reiterated at Buy by Stifel After ASCO Presentation on Bezuclastinib

June 1, 2026 7:31 AM

Stifel analyst Laura Prendergast reiterated a Buy rating and $45.00 price target on Cogent (NASDAQ: COGT).The analyst commented, " At ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found